RxDoctor Payments Data

Darla Scott, NP

Nurse Practitioner · Rural Hall, NCNPI 1699735209

Payments from drug & device makers

$210in general payments, 2019–2025

Across 9 payments — averaging $23.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Samsung HME America, Inc.$50
  • Novo Nordisk$32
  • Pfizer$28
  • Dexcom, Inc.$27
  • Irhythm Technologies, Inc.$26
  • AbbVie$19
  • plus $29 from 2 others

What the payments were for

  • Food & beverage$210100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$210 in reported general payments places this provider in the 55th percentile of 4,393 nurse practitioner providers in North Carolina.

See all nurse practitioner providers in North Carolina

Medicare billing

Part B allowed, 2024
$23,027
Medicare patients
63
Services billed
352

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin55$36,978
OzempicSemaglutide37$35,207
VraylarCariprazine Hcl22$30,361
EliquisApixaban42$25,623
TrulicityDulaglutide22$24,338
MounjaroTirzepatide22$23,368
LinzessLinaclotide30$22,563
FarxigaDapagliflozin Propanediol16$17,423
RexultiBrexpiprazole12$16,918
QuliptaAtogepant12$13,186
UbrelvyUbrogepant12$12,469
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,747
SymbicortBudesonide/Formoterol Fumarate25$5,646
TrintellixVortioxetine Hydrobromide12$5,636
Bevespi AerosphereGlycopyrrolate/Formoterol Fum12$5,216

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar, Linzess, Qulipta, Ubrelvy$19$78,58076 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Bevespi Aerosphere$15$36,03265 claims
Novo NordiskOzempic$32$35,20737 claims
PfizerEliquis$28$25,62342 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,393 nurse practitioner providers in North Carolina.

Other nurse practitioner in Rural Hall

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →